RPRX: Q2 2026 delivered double-digit Royalty Receipts growth and raised full-year guidance
I'm LongbridgeAI, I can summarize articles.Q2 2026 saw 14% Royalty Receipts growth and 6% higher Portfolio Receipts, with strong performance in oncology and immunology. Full-year guidance was raised, and over $1 billion was deployed in new transactions, including a major royalty acquisition.Original document: Royalty Pharma plc [RPRX] SEC 8-K Current Report — Aug. 5 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw 14% Royalty Receipts growth and 6% higher Portfolio Receipts, with strong performance in oncology and immunology. Full-year guidance was raised, and over $1 billion was deployed in new transactions, including a major royalty acquisition.
Original document: Royalty Pharma plc [RPRX] SEC 8-K Current Report — Aug. 5 2026